NewsSocial Healthcare

Cipla launches initiative to improve access to nebulisers in rural India

The company will donate 5000 nebulizers to primary healthcare centres in India

Cipla announced a first-of-its-kind initiative to improve access to nebulisation therapy specifically for patients in the rural sections of the country. Cipla’s respiratory medications have helped millions of asthmatic patients breathe free across the country with the company’s guiding purpose of “Caring for Life”.

Cipla aims to distribute 5000 nebulisers to primary health care setups in India where nebulisation therapy is not available currently, thus enabling access for the masses. These CHCs (Community Health Centers) /PHCs (Primary Health Centers) across several states in the country namely – Maharashtra, Uttar Pradesh, Rajasthan, West Bengal, Andhra Pradesh, Telangana, Tamil Nadu, Uttarakhand, Punjab, Sikkim will be adopted by Cipla to create good nebulisation centres, spread awareness regarding the therapy and undertake training for the associated paramedical staff on the science of safe nebulisation practices.

Cipla is also attempting to create a World Record of making the ‘largest nebulizer sentence’ with these 5000 nebulizers. The statement reads ‘Breathe Free.’ and it will be recorded in the Guinness Book of World Records.

Achin Gupta, CEO, Cipla India Business said, “In line with our purpose of ‘Caring for Life’ we aim to address the low awareness and gaps in nebulization therapy for acute asthma across rural areas. The adoption of these centres under the aegis of Cipla across the nine states within the country will help us reach far and wide to address the challenge of access to nebulisation therapy in our country. We aim to help as many patients as we can with respiratory disorders visiting these primary health setups for management of their acute episodes and to benefit from this cause enormously.”

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close